Imitinab (Gleevec) in the treatment of chronic myeloid luekemia (CML)
نویسندگان
چکیده
منابع مشابه
Perforation of the Colon During Imatinib Mesylate (Gleevec) Treatment in a Patient with Chronic Myeloid Leukemia (CML)
Imatinib (Gleevec; STI-571) is a tyrosine-kinase inhibitor (TKI) used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) as well as gastrointestinal stromal tumor (GIST). The most common adverse effects with imatinib include superficial edema, muscle cramps, musculoskeletal pain, rash, fatigue, headache, and gastrointesti...
متن کاملMolecular Monitoring and Treatment of Chronic Myeloid Leukemia (CML)
The advances in the treatment strategies in CML epitomize the concept of personalized medicine. These rapid developments towards cure of CML are acutely dependent on our ability to monitor therapeutic response to the drugs and fine-tune the therapy to the challenges posed by drug resistance from development of target site mutations. The fundamental requirement for success of targeted therapy in...
متن کاملMonitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
The aim of oral tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML) is to get ideal hematological, cytogenetic, molecular responses at the critical time points. The depth of the response obtained with TKI and the time to achieve this response are both important in predicting the prognosis in patients with CML. The high efficacy of the TKI treatment of CML has prompted th...
متن کاملPhiladelphia-Negative (Ph-) Chronic Myeloid Leukemia (CML): Comparison With Ph' CML and Chronic Myelomonocytic Leukemia
To better understand the Philadelphia-negative (Ph-) chronic myeloid leukemia (CML) and its relationships with Philadelphia-positive (Ph') CML and chronic myelomonocytic leukemia (CMML), a study was undertaken by the Groupe Franpais de Cytogenetique Hematologique. Thirty-five PhCML patients were investigated and compared with 55 chronic phase Ph+ CML and 100 CMML patients. There were 12 M-BCR p...
متن کاملDisease management and treatment of chronic myeloid leukemia (CML): Experience from the patient (pt) perspective.
6606 Background: Over the last decade, BCR-ABL inhibitors have improved clinical prognoses of pts with CML. Few studies have evaluated attributes related to CML disease and treatment and their impact on pt management in a real-world setting. This study aims to understand the impact of CML disease and treatment on quality of life (QoL), treatment adherence, and daily productivity from the pt per...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The FASEB Journal
سال: 2006
ISSN: 0892-6638,1530-6860
DOI: 10.1096/fasebj.20.5.a1132